{"id":70463,"date":"2026-04-28T18:49:12","date_gmt":"2026-04-28T18:49:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/70463\/"},"modified":"2026-04-28T18:49:12","modified_gmt":"2026-04-28T18:49:12","slug":"is-novo-nordisk-cpsenovo-b-pricing-reflect-its-recent-share-price-swings-and-growth-outlook","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/70463\/","title":{"rendered":"Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook"},"content":{"rendered":"\n

Find winning stocks<\/a> in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.<\/p>\n

With Novo Nordisk on many watchlists, the key question right now is whether the current share price reflects its underlying value or if the market is mispricing the stock.<\/p>\n

Over the past week the share price has returned 7.6%, 16.3% over the last month, but is still showing a 19.5% decline year to date and a 34.5% decline over the past year, following a 49.1% decline over three years and a 29.1% gain over five years.<\/p>\n

Recent coverage has focused on Novo Nordisk\u2019s positioning in pharmaceuticals and how sentiment has shifted as investors reassess growth expectations and risk. This helps explain the mix of shorter term gains and longer term declines. This context matters because it shapes how the market is currently framing both the opportunities and the risks around the stock.<\/p>\n

On Simply Wall St\u2019s valuation checks Novo Nordisk scores 5 out of 6. The rest of this article will walk through what different valuation approaches say about the shares, and then finish with a framework that can help you think about value in an even more complete way.<\/p>\n

Find out why Novo Nordisk’s -34.5% return over the last year is lagging behind its peers.<\/a><\/p>\n

Approach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis <\/p>\n

A Discounted Cash Flow model takes projected future cash flows, then discounts them back to today to estimate what the business could be worth right now.<\/p>\n

For Novo Nordisk, the latest twelve month Free Cash Flow is DKK 52.1b. Using a 2 Stage Free Cash Flow to Equity model, analysts have provided explicit forecasts out to 2030, with Simply Wall St extrapolating further to 2035. By 2030, projected Free Cash Flow is DKK 107.4b, and the later extrapolated years reach around DKK 145.9b of annual Free Cash Flow in 2035, all still expressed in DKK.<\/p>\n

Discounting these projected cash flows back to today results in an estimated intrinsic value of DKK 769.11 per share. Compared with the current share price, this DCF output suggests the stock is trading at a 65.4% discount to that estimate, which indicates it appears significantly undervalued on this model alone.<\/p>\n

Result: UNDERVALUED<\/p>\n

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 65.4%. Track this in your watchlist<\/a> or portfolio<\/a>, or discover 237 more high quality undervalued stocks<\/a>.<\/p>\n

\"NOVO<\/a> NOVO B Discounted Cash Flow as at Apr 2026 <\/p>\n

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Novo Nordisk.<\/a><\/p>\n

Approach 2: Novo Nordisk Price vs Earnings <\/p>\n

For a profitable company like Novo Nordisk, the P\/E ratio is a useful way to relate what you pay for each share to the earnings that business is currently generating. It helps you see how much the market is willing to pay per unit of profit.<\/p>\n

Story Continues <\/p>\n

What counts as a \u201cnormal\u201d P\/E depends on how investors see the balance between growth potential and risk. Higher expected growth and lower perceived risk usually support a higher P\/E. In contrast, lower growth expectations or higher risk tend to pull it down.<\/p>\n

Novo Nordisk currently trades on a P\/E of 11.51x. That sits well below the Pharmaceuticals industry average of 22.50x and also below the peer group average of 26.23x. Simply Wall St\u2019s proprietary \u201cFair Ratio\u201d for Novo Nordisk is 22.47x, which reflects what the P\/E might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks.<\/p>\n

This Fair Ratio aims to be more tailored than a simple comparison with industry or peers because it adjusts for company level characteristics rather than treating all pharmaceutical stocks as interchangeable. Setting Novo Nordisk\u2019s current P\/E of 11.51x against the Fair Ratio of 22.47x points to the shares looking undervalued on this metric.<\/p>\n

Result: UNDERVALUED<\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B P\/E Ratio as at Apr 2026 <\/p>\n

P\/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies<\/a>.<\/p>\n

Upgrade Your Decision Making: Choose your Novo Nordisk Narrative <\/p>\n

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, a simple tool on Simply Wall St\u2019s Community page that lets you attach a clear story about Novo Nordisk to specific assumptions for its future revenue, earnings, margins and fair value. You can then compare that fair value with today\u2019s price to decide whether the stock looks attractive to you or not.<\/p>\n

Instead of only looking at a DCF or P\/E, you pick or build a Narrative, which ties together a view on issues like GLP 1 market size, competition, pricing and patents with a full forecast. The platform then turns this into a fair value so you can see how that story translates into numbers.<\/p>\n

Because Narratives are shared and used by millions of investors on Simply Wall St, they offer an accessible way to see different viewpoints side by side. They also update automatically when new information such as earnings, news or regulatory decisions is fed into the underlying forecasts.<\/p>\n

For Novo Nordisk, for example, one investor Narrative on the Community page currently assumes a fair value of DKK 287 per share, while another assumes DKK 1,036 per share. Seeing these two endpoints, and the stories behind them, can help you decide which version of the future feels closer to your own view before you act.<\/p>\n

Do you think there’s more to the story for Novo Nordisk? Head over to our Community to see what others are saying!<\/a><\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B 1-Year Stock Price Chart <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…\n","protected":false},"author":2,"featured_media":69813,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[944,1382,946,23467,272,948],"class_list":{"0":"post-70463","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-dcf","9":"tag-dkk","10":"tag-free-cash-flow","11":"tag-growth-expectations","12":"tag-novo-nordisk","13":"tag-share-price"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116483834897933668","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/70463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=70463"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/70463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/69813"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=70463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=70463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=70463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}